Patent Application
20080021080
The present invention relates to 5-lipoxygenase inhibitors.
Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases.
Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.
The lipoxygenases are non-heme, non-sulfur iron dioxygenases that act on lipid substrates containing one or more 1,4-pentadiene moieties to form hydroperoxides. 5-Lipoxygenase is a key enzyme that catalyses the first two steps in the oxygenation of arachidonic acid, which is converted to biologically active leukotrienes, namely leukotriene B4 (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 196-201(6)) and cysteinyl leukotrienes. Leukotrienes play important role in the pathophysiology of inflammatory/allergic diseases including bronchial asthma (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 264-273(10)), allergic rhinitis (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 235-243(9)), urticaria, atopic dermatitis (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 305-308(4)), chronic obstructive pulmonary disease (Eur. Respir. J., 2003, 22: 926-930). Incidence of allergic/inflammatory diseases are on the rise world over (Expert Opinion on Therapeutic Targets, Volume 3, Number 2, June 1999, pp. 229-240(12); Expert Opinion on Investigational Drugs, Volume 10, Number 7, 1 Jul. 2001, pp. 1361-1379(19)).
A variety of stimuli namely antigen-antibody reaction, cold or hyperosmotic shock etc, that elevates intracellular calcium level, can evoke arachidonic acid release from cell membrane under the influence of cytosolic phospholipase A2. Arachidonic acid is transferred to nuclear membrane by 5-lipoxygenase binding protein (FLAP) and acted upon by 5-lipoxygenase enzyme to generate 5-hydroperoxyeicosatetraenoic acid (HPETE). HPETE is converted to LTA4 by 5-lipoxygenase. Depending upon cell type, LTA4 is converted to either cysteinyl leukotrienes and/or leukotriene B14 (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 196-201(6); Current Drug Targets—Inflammation & Allergy, Volume 1, Number 1, March 2002, pp. 23-44(22); Drug Safety, Volume 26, Number 7, 2003, pp. 483-518(36)).
Leukotrienes are generated by a variety of inflammatory cell types. Neutrophils and monocytes generate LTB4 whereas mast cells, basophils, eosinophils and bronchial epithelial cells produce cysteinyl leukotrienes. LTB4 acts as a chemo attractant for neutrophils through specific cell surface receptors. Cysteinyl leukotrienes, which include LTC4, LTD4 and LTE4, act on CysLT1 and CysLT2 receptors and increase bronchial smooth muscle contractility, promote mucosal secretion, increase vascular permeability and encourage eosinophils recruitment. (Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, S210-S213; Thorax 2000, 55, S32-S37; Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 196-201(6); Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 220-228(9); Drug Safety, Volume 26, Number 7, 2003, pp. 483-518(36)).
There is evidence suggesting that cysteinyl leukotrienes can increase airway smooth muscle contractility in preclinical (Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, S214-S219) and clinical studies (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 220-228(9)). Inhalation of leukotrienes also increases influx of inflammatory cells in the airway of animals (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 220-228(9)) and humans (Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, S210-S213). In patients with asthma, urinary excretion of LTE4 correlates with exercise or cold air induced bronchoconstriction (Lancet, 1, 584, 1989) allergen induced early and late phase response (Clinical & Experimental Allergy, Volume 28, Number 11, 1 Nov. 1998, pp. 1332-1339(8); Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, S210-S213), as well as with reduction of FEV1 in patients with nocturnal asthma (Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, S233-S237). Efficacy of leukotriene biosynthesis inhibitors and leukotriene receptor antagonists have been tested in numerous trials involving asthma patients (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 254-260(7); Drug Safety, Volume 26, Number 7, 2003, pp. 483-518(36); The New England Journal of Medicine, Volume 340:197-206, 1999; Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, S233-S237).
Evidence is emerging that leukotrienes also contribute towards pathophysiology of COPD. Two major cell types, neutrophils and macrophages, that generate LTB4 and are modulated by the same in turn are believed to participate in the pathogenesis of COPD (Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, S210-S213). Patients with COPD exhibit elevated sputum neutrophilia and LTB4 levels (Chest 2002; 121:197S-200S). Elevated levels of LTB4 were shown to be present in the exhaled breath condensate of COPD patients (Thorax 2003; 58: 585-588) as well as in patients experiencing exacerbation of COPD (Thorax 2003; 58: 294-298). Inhibitors of leukotriene biosynthesis as well as LTB4 receptor antagonists have shown to reduce airway reactivity, airway inflammation and airway neutrophilia in animals (J. Clin. Exp. Aller. 91, 917, 1992; J. Pharmacol. Exp. Ther., 2001, 297: 458-466) as well as in human subjects (Thorax, 1996, 51: 1178-1184; Chest 2002; 122: 289S-293S). Cysteinyl leukotriene antagonists like Montelukast has shown protective effect in hypertonic saline induced bronchoconstriction in COPD patients (Eur. Respir. J., 2003, 22: 926-930).
Similarly, evidence is emerging based on animal and human data that leukotriene pathway modulators can play role in arthritis (J. Pharmacol. Exp. Ther., 1998, 285: 946-954), allergic rhinitis and urticaria (Clinical & Experimental Allergy Reviews, Volume 1, Number 3, November 2001, pp. 235-243(9)), cancer (Current Drug Targets—Inflammation & Allergy, Volume 3, Number 1, March 2004, pp. 19-33(15)), inflammatory bowel disease (Laboratory Investigation, 2005, 85, 808-822; Indian Journal of Experimental Biology Vol. 42, July 2004, pp. 667-673), acne (Dermatology 210(1), 36-38, 2005 ; Arch. Dermatol. 2003;139: 668-670), pruritis (J. Invest. Dermatol. 117, 1621, 2001), as well as atherosclerosis (N. Engl. J. Med. 2004, 350, 29-37; N. Engl. J. Med. 2004, 350, 4-7, Med. Res. Rev. 24, 399, 2004).
Several leukotriene receptor antagonists, Montelukast, Zafirlukast, and Pranlukast, and one 5-lipoxygenase inhibitor, Zileuton, has been launched in the market. Both categories of molecules have shown efficacy in clinical trials of bronchial asthma. Inhibitors of 5-lipoxygenase exhibit greater potential to exhibit efficacy in COPD as well because of their inhibitory effect on LTB4 mediated processes. However, commercially available 5-lipoxygenase inhibitor is associated with poor pharmacokinetic property and adverse events like elevation of hepatic transaminases. This has prompted the search for novel inhibitors of 5-lipoxygenase with improved pharmacokinetic profiles and reduced adverse effects.
WO 96/14307, WO 96/40660, WO 98/03492 and WO 98/03494 encompass substituted benzylamine derivatives, which have been said to be useful in the diagnosis and treatment of feeding disorders such as obesity, bulimia and cardiovascular diseases such as essential hypertension and congestive heart failure due to the binding of these compounds to human Neuropeptide Y1 receptors.
WO 96/31485 discloses 1,3-dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives, which have been said to have PDE IV and cytokine activity.
U.S. Pat. No. 5,883,106 discloses compounds, which have been described to have the ability to inhibit 5-lipoxygenase enzyme.
The present invention provides 5-lipoxygenase inhibitors, which can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases.
Pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, tautomers, racemates, regioisomers, prodrugs, metabolites, polymorphs or N-oxides of these compounds having the same type of activity are also provided.
Pharmaceutical compositions containing the compounds, which may also contain pharmaceutically acceptable carriers or diluents can be used for treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases.
Other aspects will be set forth in the accompanying description which follows and in part will be apparent from the description or may be learnt by the practice of the invention.
In accordance with one aspect, there are provided compounds having the structure of Formula I,
and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, tautomers, racemates, regioisomers, prodrugs, metabolites, polymorphs or N-oxides, wherein G can be O or S, Z can be —(CH2)n—X— or —X—(CH2)n—, X can be —NR1, —O— or —S—, n can be 0-2, R1 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heteroaryl, heterocyclyl, (heteroaryl)alkyl, (heterocyclyl)alkyl, R2 can be —CN, —COR3, 5-membered heteroaryl or hetereocyclyl, R3 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heteroaryl, heterocyclyl, (heteroaryl)alkyl, (heterocyclyl)alkyl, —OR1, —SR1 or —N(R1)2.
The following definitions apply to terms as used herein.
The term “alkyl,” unless otherwise specified, refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms. This term can be exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-decyl, tetradecyl, and the like. Alkyl groups may be substituted further with one or more substituents selected from alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, aryl, heterocyclyl, heteroaryl, arylthio, thiol, alkylthio, aryloxy, nitro, aminosulfonyl, aminocarbonylamino, —C(═O)heteroaryl, —C(═O)heterocyclyl, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg {wherein w is an integer from 0-4 and Rg is hydrogen, ORf, —NRfRq, —NHORz (wherein Rz is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl) or —NHOH}, —C(═O)NRfRq, —NHC(═O)NRfRq , —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf {wherein Rf and Rq are hydrogen, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, (heterocyclyl)alkyl, (heteroaryl)alkyl)}, guanidine or —S(O)n Rd (wherein n is 0-2, Rd is alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl). Unless otherwise constrained by the definition, alkyl substituents may be further substituted by 1-3 substituents selected from alkyl, carboxy, nitro, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf (wherein w, Rg, Rf and Rq are the same as defined earlier), hydroxy, alkoxy, halogen, CF3, cyano, guanidine or —S(O)nRd, (wherein n and Rd are the same as defined earlier); or an alkyl group also may be interrupted by 1-5 atoms of, groups independently selected from oxygen, sulfur or —NRa— {wherein Ra is selected from hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, acyl, aralkyl, —C(═O)ORf (wherein Rf is the same as defined earlier) or —C(═O)NRfRq (wherein Rf and Rq are as defined earlier)}. Unless otherwise constrained by the definition, all substituents may be substituted further by 1-3 substituents selected from alkyl, carboxy, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf, (wherein w, Rg, Rf and Rq are the same as defined earlier), hydroxy, alkoxy, halogen, CF3, cyano, guanidine or S(O)nRd, (wherein n and Rd are the same as defined earlier); or an alkyl group as defined above, that has both substituents as defined above and is also interrupted by 1-5 atoms or groups as defined above.
The term “alkenyl,” unless otherwise specified, refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group having from 2 to 20 carbon atoms with cis, trans, or geminal geometry. In the event that alkenyl is attached to a heteroatom, the double bond cannot be alpha to the heteroatom. Alkenyl groups may be substituted further with one or more substituents selected from alkyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf, (wherein w, Rg, Rf and Rq are the same as defined earlier), alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryl, aralkyl, aryloxy, heterocyclyl, heteroaryl, (heterocyclyl)alkyl, (heteroaryl)alkyl, anminosulfonyl, aminocarbonylamino, alkoxyamino, nitro, guanidine or (SO)nRd (wherein n and Rd are the same as defined earlier). Unless otherwise constrained by the definition, alkenyl substituents optionally may be substituted further by 1-3 substituents selected from alkyl, carboxy, hydroxy, alkoxy, halogen, —CF3, cyano, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf (wherein w, Rg, Rf and Rq are the same as defined earlier) guanidine or (SO)nRd (wherein n and Rd are the same as defined earlier).
The term “alkynyl,” unless otherwise specified, refers to a monoradical of an unsaturated hydrocarbon, having from 2 to 20 carbon atoms. In the event that alkynyl is attached to a heteroatom, the triple bond cannot be alpha to the heteroatom. Alkynyl groups may be substituted further with one or more substituents selected from alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, alkoxycarbonyl amino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryl, aralkyl, aryloxy, aminosulfonyl, aminocarbonylamino, nitro, heterocyclyl, heteroaryl, (heterocyclyl)alkyl, (heteroaryl)alkyl, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf, (wherein w, Rg, Rf and Rq are the same as defined earlier), guanidine or —(SO)nRd (wherein n and Rd are the same as defined earlier). Unless otherwise constrained by the definition, alkynyl substituents optionally may be substituted further by 1-3 substituents selected from alkyl, carboxy, hydroxy, alkoxy, halogen, CF3, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf (wherein w, Rg, Rf and Rq are the same as defined earlier), cyano, guanidine or —(SO)nRd (where n and Rd are the same as defined earlier).
The term “cycloalkyl,” unless otherwise specified, refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, which may optionally contain one or more olefinic bonds, unless otherwise constrained by the definition. Such cycloalkyl groups can include, for example, single ring structures, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, and the like, or multiple ring structures, including adamantanyl, and bicyclo [2.2.1] heptane, or cyclic alkyl groups to which is fused an aryl group, for example, indane, tetrahydroquinoline and the like. Spiro and fused ring structures can also be included. Cycloalkyl groups may be substituted further with one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryl, aralkyl, aryloxy, aminosulfonyl, aminocarbonylamino, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf, (wherein w, Rg, Rf and Rq are the same as defined earlier), nitro, heterocyclyl, heteroaryl, (heterocyclyl)alkyl, (heteroaryl)alkyl, guanidine or (SO)nRd (wherein n and Rd are the same as defined earlier). Unless otherwise constrained by the definition, cycloalkyl substituents-, optionally may be substituted further by 1-3 substituents selected from alkyl, carboxy, hydroxy, alkoxy, halogen, CF3, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf, (wherein w, Rg, Rf and Rq are the same as defined earlier), cyano, guanidine or (SO)nRd (wherein n and Rd are the same as defined earlier).
The term “(cycloalkyl)alkyl” refers to alkyl-cycloalkyl group linked through alkyl portion, wherein the alkyl and cycloalkyl are as defined earlier.
The term “alkoxy” denotes the group O-alkyl wherein alkyl is the same as defined above.
The term “aryl,” unless otherwise specified, refers to carbocyclic aromatic groups, for example, phenyl, biphenyl or napthyl ring and the like, optionally substituted with 1 to 3 substituents selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, alkoxy, acyl, aryloxy, CF3, cyano, nitro, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf, (wherein w, Rg, Rf and Rq are the same as defined earlier), guanidine, —(SO)nRd (wherein n and Rd are the same as defined earlier), carboxy, heterocyclyl, heteroaryl, (heterocyclyl)alkyl, (heteroaryl)alkyl or aminocarbonylamino. The aryl group optionally may be fused with a cycloalkyl group, wherein the cycloalkyl group may optionally contain heteroatoms selected from O, N or S.
The term “aralkyl,” unless otherwise specified, refers to alkyl-aryl linked through an alkyl portion (wherein alkyl is as defined above) and the alkyl portion contains 1-6 carbon atoms and aryl is as defined above. Examples of aralkyl groups include benzyl, phenyl ethyl, phenylpropyl and the like.
The term “aryloxy” denotes, the group O-aryl, wherein aryl is as defined above.
The term “cycloalkoxy” denotes the group O-cycloalkyl, wherein cycloalkyl is as defined above.
The term “carboxy,” as defined herein, refers to —C(═O)ORf, wherein Rf is the same as defined above.
The term “heteroaryl,” unless otherwise specified, refers to an aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having from 8 to 10 ring atoms, with one or more heteroatom(s) independently selected from N, O or S optionally substituted with 1 to 4 substituent(s) selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, acyl, carboxy, aryl, alkoxy, oxo, aralkyl, cyano, nitro, heterocyclyl, heteroaryl, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf (wherein w, Rg, Rf and Rq are the same as defined earlier) or guanidine. Unless otherwise constrained by the definition, the substituents are attached to a ring atom, i.e., carbon or heteroatom in the ring.
The term ‘heterocyclyl,” unless otherwise specified, refers to a non-aromatic monocyclic or bicyclic cycloalkyl group having 5 to 10 atoms wherein 1 to 4 carbon atoms in a ring are replaced by heteroatoms selected from O, S or N, and optionally are benzofused or fused heteroaryl having 5-6 ring members and/or optionally are substituted, wherein the substituents are selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, acyl, aryl, alkoxy, aralkyl, cyano, nitro, oxo, carboxy, heterocyclyl, heteroaryl, —NRfRq, —CH═NOH, —(CH2)wC(═O)Rg, —C(═O)NRfRq, —NHC(═O)NRfRq, —O—C(═O)NRfRq, —O—C(═O)Rf, —O—C(═O)ORf (wherein w, Rg, Rf and Rq are the same as defined earlier) or guanidine. Heterocyclyl can optionally include rings having one or more double bonds. Unless otherwise constrained by the definition, the substituents are attached to the ring atom, i.e., carbon or heteroatom in the ring. Also, unless otherwise constrained by the definition, the heterocyclyl ring optionally may contain one or more olefinic bond(s).
Examples of heteroaryl and heterocyclyl groups include oxazolyl, imidazolyl, pyrrolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, thiazolyl, oxadiazolyl, oxazolidinyl, thiadiazolyl, thiazolyl, thiazolinyl, thienothiazolyl, triazolone, imidazolone, thioimidazolone, thienooxazolyl, thienoimidazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, triazinyl, furanyl, benzofuranyl, benzooxathiolone, oxathiazole, oxathiadiazole, thiotriazolone, indolyl, benzthiazolyl, oxathiazin , benzoxazolyl, benzimidazolyl, oxazolidinyl, tetrahydrofuranyl, dihydrofuranyl, morpholinyl, dihydropyridinyl, isothiazolidinyl, dihydroisoxazolyl, dihydrobenzofuryl, azabicyclohexyl, dihydroindolyl, isoindole 1,3-dione, piperidinyl or piperazinyl and the like.
“(Heteroaryl)alkyl” refers to alkyl-heteroaryl group linked through alkyl portion, wherein the alkyl and heteroaryl are as defined earlier.
“(Heterocyclyl)alkyl” refers to alkyl-heterocyclyl group linked through alkyl portion, wherein the alkyl and heterocyclyl are as defined earlier.
“Acyl” refers to —C(═O)Rz wherein Rz is same as defined earlier.
“Thiocarbonyl” refers to —C(═S)R″′, wherein R″′ is selected from hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, amine or substituted amine. Unless otherwise constrained by the definition, all substituents optionally may be substituted further by 1-3 substituents selected from alkyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, carboxy, hydroxy, alkoxy, halogen, CF3, cyano, —C(═O)NRfRq, —O(C═O)NRfRq (wherein Rf and Rq are the same as defined earlier), —(SO)nRd (wherein n and Rd are the same as defined earlier).
“Amine,” unless otherwise specified, refers to —NH2. “Substituted amine,” unless otherwise specified, refers to —N(Rk)2, wherein each Rk independently is selected from hydrogen {provided that both Rk groups are not hydrogen (defined as “amino”)}, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, acyl, —C(═O)NRfRq, —NHC(═O)NRfRq, or —NHC(═O)ORf (wherein Rf and Rq are as defined earlier).
The term “halogen” refers to fluorine, chlorine, bromine or iodine.
The compounds of the present invention can be used for treating bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases.
In accordance with yet another aspect, there are provided processes for the preparation of the compounds as described herein.
The compounds described herein may be prepared by techniques well known in the art and familiar to the average synthetic organic chemist. In addition, the compounds of present invention may be prepared by the following reaction sequences as depicted in Schemes I, II and III.
Compounds of Formula XVI and XVII can be prepared by following Scheme I. Accordingly, compounds of Formula II can be coupled with ammonium carbonate to give compounds of Formula III (wherein X1 can be halogen), which on dehydration can give compounds of Formula IV, which on reaction with compounds of Formula V (wherein X1 can be halogen) can give compounds of Formula VI, which on reaction with compounds of Formula VII can give compounds of Formula VIII (wherein Z can be the same as defined earlier), which on reaction with compounds of Formula IX (wherein X1 can be halogen) can give compounds of Formula X (wherein Ar can be aryl), which on reaction with hydrazine can give compounds of Formula XI, which on reaction with compounds of Formula XII can give compounds of Formula XIII (wherein R1 can be the same as defined earlier), which
The coupling of compounds of Formula II with ammonium carbonate to give compounds of Formula III can be carried out in the presence of one or more of coupling agents, for example, 1-(3-dimethylaminopropyl)-3-ethyl-carbodimide, N,N′-dicyclohexylcarbodiimide, 2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), (benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate (BOP), propane phosphoric acid anhydride (T3P), O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), S-(1-oxido-2-pyridinyl)-1,1,3,3-tetramethylthiouronium tetrafluoroborate (TOTT), N,N,N′,N′-tetramethyl-O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)uronium tetrafluoroborate (TDBTU), O-(1,2-dihydro-2-oxo-pyridyl]-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TPTU), O-((ethoxycarbonyl)cyanomethylenamino)-N,N′,N′-tetramethyluronium tetrafluoroborate (TOTU), chlortripyrrolidino phosphoniumhexafluorophosphate (PyClop), benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), chlorodipyrrolidinocarbenium hexafluorophosphate(PyClU), benzotriazol-1-yloxy)dipiperidinocarbenium hexafluorophosphate (HBPipU) or mixtures thereof.
The coupling of compounds of Formula II with ammonium carbonate can be carried out in the presence of one or more of additives or activating agents, for example, 1-hydroxybenzotriazole, acetone oxime, 2-hydroxypyridine, N-hydroxysuccinimide, pentafluorophenol or mixtures thereof.
The coupling of compounds of Formula II with ammonium carbonate can be carried out in the presence of one or more of organic bases, for example, N-methylmorpholine, N-methylmorpholine oxide, 1-methylpiperidine, triethylamine, tribenzylamine, piperidine, N-ethyldiisopropylamine, N-ethylmorpholine, 2,6-lutidine or mixtures thereof.
The coupling of compounds of Formula II with ammonium carbonate can be carried out in one or more of solvents, for example, polar aprotic solvents, for example, dimethylformamide, dimethyl acetamide or dimethylsulphoxide, ethers, for example, tetrahydrofuran, dioxane or diethyl ether, nitriles, for example, acetonitrile or dimethoxyacetonitrile or mixtures thereof.
The dehydration of compounds of Formula III to give compounds of Formula IV can be carried out in the presence of one or more of dehydrating agents, for example, trifluoroacetic anhydride, trifluromethanesulfonic anhydride or mixtures thereof.
The dehydration of compounds of Formula III can be carried out in the presence of one or more of organic bases, for example, morpholine, N-methylmorpholine, 1-methylpiperidine, trimethylamine, triethylamine, tribenzylamine, N-ethyltriisopropylamine, piperidine or mixtures thereof.
The dehydration of compounds of Formula III can be carried out in one or more of solvents, for example, polar aprotic solvents, for example, dimethylformamide or dimethylsulphoxide, ethers, for example, tetrahydrofuran, dioxane or diethyl ether, nitrites, for example, acetonitrile or dimethoxyacetonitrile or mixtures thereof.
The reaction of compounds of Formula IV with compounds of Formula V to give compounds of Formula VI can be carried out in the presence of one or more of phase transfer catalysts, for example, 15-crown-5 (15-c-5), cetyltrimethylammonium bromide (CTMAB), dibenzo-18-crown-6 (DB-18-c-6), dicyclohexano-18-crown-6 (DC-18-c-6), 18-crown-6 (18-c-6), N-dodecyl-N-methylephedrinium bromide (DMCOH), hexamethyl phosphoric triamide (HMPT), cetylpyridinium bromide (NCPB), N-benzylquininium chloride (QUIBEC), tetra-n-butylammonium bromide (TBAB), tetra-n-butylammonium chloride (TBAC), tetra-n-butylammonium hydroxide (TBAH), tetra-n-butylammonium hydrogen sulfate (TBAHS), tetra-n-butylammonium iodide (TBAI), tetraethylammonium chloride hydrate (TEAC), tri-n-butylamine (TBA), benzyltributylammonium bromide (TBBAB), hexadecyltributylphosphonium bromide (TBHDPB), benzyltriethylammonium bromide (TEBAB), benzyltriethylammonium chloride (TEBA), hexadecyltriethylammonium chloride (TEHDAC), tetramethylammonium chloride (TMAC), hexadecyltrimethylammonium chloride (TMHDAC), octyltrimethylammonium chloride (TMOAC) or mixtures thereof.
The reaction of compounds of Formula IV with compounds of Formula V can be carried out in the presence of one or more of iodinating reagents, for example, alkali metal iodides, for example, sodium iodide, potassium iodide, lithium iodide or mixtures thereof.
The reaction of compounds of Formula IV with compounds of Formula V can be carried out in the presence of one or more of bases, for example, alkali metal hydrides, for example, sodium hydride or potassium hydride, alkali metal amides, for example, sodium amide, potassium amide or lithium amide, alkali metal alkoxides, for example, sodium methoxide, sodium ethoxide, sodium tert-butoxide or potassium tert-butoxide, alkali metal hydroxides, for example, sodium hydroxide or potassium hydroxide or mixtures thereof.
The reaction of compounds of Formula IV with compounds of Formula V can be carried out in one or more of solvents, for example, alcohols, for example, methanol, ethanol or propanol, polar aprotic solvents, for example, dimethylformamide or dimethylsulphoxide, ethers, for example, tetrahydrofuran, dioxane or diethyl ether or mixtures thereof.
The reaction of compounds of Formula VI with compounds of Formula VII to give compounds of Formula VIII can be carried out in the presence of one or more of bases, for example, amines, for example, N-ethyldiisopropylamine, triethylamine or dimethylaminopyridine, alkali metal alkoxides, for example, sodium tert-butoxide, potassium tert-butoxide, sodium methoxide, lithium methoxide, potassium methoxide, cesium methoxide or sodium ethoxide, alkali metal hydroxides, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or cesium hydroxide, alkali metal halides, for example, potassium fluoride or cesium fluoride, alkali metal carbonates, for example, sodium carbonate, potassium carbonate or cesium carbonate or mixtures thereof.
The reaction of compounds of Formula VI with compounds of Formula VII can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, methyl tert-butyl ether, dioxane, cyclopentylmethylether or tetrahydrofuran, hydrocarbons, for example, toluene or xylene, polar aprotic solvents, for example, dimethylformamide, dimethyl sulphoxide or N-methylpyrrolidone or mixtures thereof.
The reaction of compounds of Formula VIII with compounds of Formula IX to give compounds of Formula X can be carried out in the presence of one or more of organic bases, for example, pyridine, ethylamine, triethylamine, N-ethyldiisopropyl amine, piperidine or mixtures thereof.
The reaction of compounds of Formula VIII with compounds of Formula IX can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, methyl tert-butyl ether, dioxane, cyclopentylmethylether or, tetrahydrofuran, hydrocarbons, for example, toluene or xylene, halogenated solvents, for example, dichloromethane, dichloroethane, carbon tetrachloride or chloroform or mixtures thereof.
The reaction of compounds of Formula X with hydrazine to give compounds of Formula XI can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, methyl tert-butyl ether, dioxane, cyclopentylmethyl ether or tetrahydrofuran, alcohols, for example, ethanol, propanol, isopropanol or cyclohexanol or mixtures thereof.
The reaction of compounds of Formula XI with compounds of Formula XII to give compounds of Formula XIII can be carried out in the optional presence of one or more organic acids, for example, acetic acid, inorganic acids, for example, hydrochloric acid or mixtures thereof.
The reaction of compounds of Formula XI with compounds of Formula XII can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, methyl tert-butyl ether, dioxane, cyclopentylmethyl ether or tetrahydrofuran, hydrocarbons, for example, toluene, or xylene, polar aprotic solvents, for example, dimethylformamide, dimethyl sulphoxide or N-methylpyrrolidone or mixtures thereof.
The reaction of compounds of Formula XIII with compounds of Formula XIV to give compounds of Formula XV can be carried out in the presence of one or more of bases, for example, amines, for example, N-ethyldiisopropylamine, triethylamine or dimethylaminopyridine, alkali metal alkoxides, for example, sodium tert-butoxide, potassium tert-butoxide, sodium methoxide, lithium methoxide, potassium methoxide or cesium methoxide or sodium ethoxide, alkali metal hydroxides, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or cesium hydroxide, alkali metal halides, for example, potassium fluoride or cesium fluoride, alkali metal carbonates, for example, sodium carbonate, potassium carbonate or cesium carbonate or mixtures thereof.
The reaction of compounds of Formula XIII with compounds of Formula XIV can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, methyl tert-butyl ether, dioxane, cyclopentylmethyl ether or tetrahydrofuran, hydrocarbons, for example, toluene or xylene, polar aprotic solvents, for example, dimethylformamide, dimethyl sulphoxide or N-methylpyrrolidone or mixtures thereof.
The hydrolysis of compounds of Formula XIII or compounds of Formula XV to give compounds of Formula XVII or compounds of Formula XVI, respectively can be carried out one or more of bases, for example, alkali metal hydroxides, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or cesium hydroxide, alkali metal halides, for example, potassium fluoride or cesium fluoride, alkali metal carbonates, for example, sodium carbonate, potassium carbonate or cesium carbonate or mixtures thereof.
The hydrolysis of compounds of Formula XIII or compounds of Formula XV can be carried out in one or more of solvents, for example, alcohols, for example, methanol, ethanol, propanol or isopropanol, polar aprotic solvents, for example, dimethylformamide or dimethylsulphoxide, ethers, for example, tetrahydrofuran, dioxane or diethyl ether or mixtures thereof.
Compounds of Formula XXI and XXIII can be prepared by following Scheme II. Accordingly, compound of Formula XVII can be reacted with compounds of Formula XVIII to give compounds of Formula XIX (wherein R4 can be hydrogen or alkyl, R5 can be alkyl and R1 and Z can be same as defined earlier), which
The reaction of compounds of Formula XVII with compounds of Formula XVIII to give compounds of Formula XIX can be carried out under refluxing.
The reaction of compounds of Formula XIX with hydroxylamine or hydrazine to give compounds of Formula XX or compounds of Formula XXII respectively can be carried out in the presence of one or more of bases, for example, alkali metal hydroxides, for example, sodium hydroxide or potassium hydroxide, alkali metal carbonates, for example, sodium carbonate, potassium carbonate, lithium carbonate or cesium carbonate, alkali metal bicarbonates, for example, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate or cesium bicarbonate or mixtures thereof.
The reaction of compounds of Formula XIX with hydroxylamine or hydrazine can be carried out in the presence of one or more of acids, for example, organic acids, for example, acetic acid or formic acid or inorganic acids, for example, hydrochloric acid.
The reaction of compounds of Formula XIX with hydroxylamine or hydrazine can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, methyl tert-butyl ether, dioxane, cyclopentylmethyl ether or tetrahydrofuran, alcohols, for example, methanol, ethanol, propanol or isopropanol or mixtures thereof.
The reaction of compounds of Formula XX or compounds of Formula XXII with compounds of Formula XIV to give compounds of Formula XXI or compounds of Formula XXIII respectively can be carried out in the presence of one or more of bases, for example, amines, for example, N-ethyldiisopropylamine, triethylamine or dimethylamino pyridine, alkali metal alkoxides, for example, sodium tert-butoxide, potassium tert-butoxide, sodium methoxide, lithium methoxide, potassium methoxide, cesium methoxide or sodium ethoxide, alkali metal hydroxides, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or cesium hydroxide, alkali metal halides, for example, potassium fluoride or cesium fluoride, alkali metal carbonates, for example, sodium carbonate, potassium carbonate or cesium carbonate, alkali metal hydrides, for example, sodium hydride or potassium hydride or mixtures thereof.
The reaction of compounds of Formula XX or compounds of Formula XXII with compounds of Formula XIV can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, methyl tert-butyl ether, dioxane, cyclopentylmethyl ether or tetrahydrofuran, hydrocarbons, for example, toluene or xylene, polar aprotic solvents, for example, dimethylformamide, dimethyl sulphoxide or N-methylpyrrolidone, alcohols, for example, ethanol or isopropanol or mixtures thereof.
Compounds of Formula XXVIII and XXXIV can be prepared by following Scheme III. Accordingly compounds of Formula XVII can be hydrolyzed to give compounds of Formula XXIV (wherein R1 and Z can be same as defined earlier),
The hydrolysis of compounds of Formula XVII to give compounds of Formula XXIV can be carried out in the presence of one or more of bases, for example, alkali metal alkoxides, for example, sodium tert-butoxide, potassium tert-butoxide, sodium methoxide, lithium methoxide, potassium methoxide, sodium ethoxide or cesium methoxide, alkali metal hydroxides, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or cesium hydroxide, alkali metal halides, for example, potassium fluoride or cesium fluoride, alkali metal carbonates, for example, sodium carbonate, potassium carbonate or cesium carbonate or mixtures thereof.
The hydrolysis of compounds of Formula XVII can be carried out in one or more of solvents, for example, alcohols, for example, methanol, ethanol, propanol or isopropanol, polar aprotic solvents, for example, dimethylformamide or dimethylsulphoxide, ethers, for example, tetrahydrofuran, dioxane or diethyl ether or mixtures thereof.
The reaction of compounds of Formula XXIV with compounds of Formula XXV to give compounds of Formula XXVI can be carried out in the presence of one or more of coupling agents, for example, 1-(3-dimethylaminopropyl)-3-ethyl-carbodimide, N,N′-dicyclohexylcarbodiimide, 2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), (benzotriazol-1-yloxy) tris-(dimethylamino)phosphonium hexafluorophosphate (BOP), propane phosphonic acid anhydride (T3P), O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), S-(1-oxido-2-pyridinyl)-1,1,3,3-tetramethylthiouronium tetrafluoroborate (TOTT), N,N,N′N′-tetramethyl-O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)uronium tetrafluoroborate (TDBTU), O-(1,2-dihydro-2-oxo-pyridyl]-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TPTU), O-((ethoxycarbonyl) cyanomethylenamino)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TOTU), chlortripyrrolidino phosphoniumhexafluorophosphate (PyClop), benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), chlorodipyrrolidinocarbenium hexafluorophosphate (PyClU), benzotriazol-1-yloxy)dipiperidinocarbenium hexafluorophosphate (HBPipU) or mixtures thereof.
The reaction of compounds: of Formula XXIV with compounds of Formula XXV can be carried out in the presence of one or more of additives or activating agents, for example, 1-hydroxybenzotriazole, acetone oxime, 2-hydroxypyridine, N-hydroxysuccinimide, pentafluorophenol or mixtures thereof.
The reaction of compounds of Formula XXIV with compounds of Formula XXV can be carried out in the presence of one or more of organic bases, for example, N-methylmorpholine, N-methylmorpholine oxide, N-ethylmorpholine, 1-methylpiperidine, triethylamine, tribenzylamine, piperidine, N-ethyldiisopropylamine, 2,6-lutidine or mixtures thereof.
The reaction of compounds of Formula XXIV with compounds of Formula XXV can be carried out in one or more of solvents, for example, polar aprotic solvents, for example, dimethylformamide or dimethylsulphoxide, ethers, for example, tetrahydrofuran, dioxane or diethyl ether, halogenated solvents, for example, dichloromethane, dichloroethane, carbon tetrachloride or chloroform or mixtures thereof.
The cyclization of compounds of Formula XXVI to give compounds of Formula XXVII can be carried out in the presence of one or more of cyclizing agents, for example, mercuric acetate, tri-n-butyltin hydride or mixtures thereof.
The cyclization of compounds of Formula XXVI can be carried out in one or more of acids, for example, acetic acid.
The cyclization of compounds of Formula XXVI can be carried out in one or more of solvents, for example, polar aprotic solvents, for example, dimethylformamide or dimethylsulphoxide or ethers, for example, tetrahydrofuran, dioxane or diethyl ether, hydrocarbons, for example, toluene or xylene or mixtures thereof.
The reaction of compounds of Formula XXVII with compounds of Formula XIV to give compounds of Formula XXVIII can be can be carried out in the presence of one or more of bases, for example, amines, for example, N-ethyldiisopropylamine, triethylamine or dimethylamino pyridine, alkali metal alkoxides, for example, sodium tert-butoxide, potassium tert-butoxide, sodium ethoxide, sodium methoxide, lithium methoxide, potassium methoxide or cesium methoxide, alkali metal hydroxides; for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or cesium hydroxide, alkali metal halides, for example, potassium fluoride or cesium fluoride, alkali metal carbonates, for example, sodium carbonate, potassium carbonate or cesium carbonate, alkali metal hydrides, for example, sodium hydride, calcium hydride or potassium hydride or mixtures thereof.
The reaction of compounds of Formula XXVII with compounds of Formula XIV can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, diethylether, methyl tert-butyl ether, dioxane, cyclopentylmethyl ether or tetrahydrofuran, hydrocarbons, for example, toluene, and xylene, polar aprotic solvents, for example, dimethylformamide, dimethylsulphoxide, dimethylacetamide or N-methylpyrrolidone, alcohols, for example, methanol, ethanol, propanol or isopropanol or mixtures thereof.
The esterification of compounds of Formula XXIV with compounds of Formula XXIX to give compounds of Formula XXX can be carried out in the presence of one or more of halogenating agents, for example, phosphorous pentachloride, phosphorous pentabromide, phosphorous trichloride, phosphorous tribromide, thionyl chloride, oxalyl chloride or mixtures thereof.
The reaction of compounds of Formula XXX with compounds of Formula XXXI to give compounds of Formula XXXII can be carried out in one or more of alcohols, for example, methanol, ethanol, propanol or mixtures thereof.
The cyclization of compounds of Formula XXXII to give compound of Formula XXXIII can be carried out in the presence of cyclizing agents, for example, triphenylphosphine.
The cyclization of compounds of Formula XXXII can be carried out in one or more of organic bases, for example, N-methylmorpholine, N-methylmorpholine oxide, N-ethylmorpholine, 1-methylpiperidine, triethylamine, tribenzylamine, piperidine, N-ethyldiisopropylamine, 2,6-lutidine or mixtures thereof.
The cyclization of compounds of Formula XXXII can be carried out in one or more of solvents, for example, halogenated solvents, for example, dichloromethane, dichloroethane, carbon tetrachloride or chloroform, nitriles, for example, acetonitrile or dimethoxyacetonitrile or mixtures thereof.
The reaction of compounds of Formula XXXIII with compounds of Formula XIV to give compounds of Formula XXXIV can be can be carried out in the presence of one or more of bases, for example, amines, for example, N-ethyldiisopropylamine, triethylamine or dimethylamino pyridine, alkali metal alkoxides, for example, sodium tert-butoxide, potassium tert-butoxide, sodium ethoxide, sodium methoxide, lithium methoxide, potassium methoxide or cesium methoxide, alkali metal hydroxides; for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or cesium hydroxide, alkali metal halides, for example, potassium fluoride or cesium fluoride, alkali metal carbonates, for example, sodium carbonate, potassium carbonate or cesium carbonate, alkali metal hydrides, for example, sodium hydride, calcium hydride or potassium hydride or mixtures thereof.
The reaction of compounds of Formula XXXIII with compounds of Formula XIV can be carried out in one or more of solvents, for example, ethers, for example, dibutyl ether, diethylether, methyl tert-butyl ether, dioxane, cyclopentylmethyl ether or tetrahydrofuran, hydrocarbons, for example, toluene, and xylene, polar aprotic solvents, for example, dimethylformamide, dimethylsulphoxide, dimethylacetamide or N-methylpyrrolidone, alcohols, for example, methanol, ethanol, propanol or isopropanol or mixtures thereof.
In the above schemes, where the specific solvents, bases, acids, iodinating agents, coupling agents, additives or activating agents, dehydrating agents, phase transfer catalysts, cyclizing agents etc., are mentioned, it is to be understood that other solvents, bases, acids, iodinating agents, coupling agents, additives or activating agents, dehydrating agents, phase transfer catalysts, cyclizing agents etc., known to those skilled in the art may be used. Similarly, the reaction temperature and duration may be adjusted according to the desired needs.
An illustrative list of compounds of the invention prepared by following Schemes I, II and III include:
The term “pharmaceutically acceptable” means approved by regulatory agency of the federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
The term “pharmaceutically acceptable salts” refers to derivatives of compounds that can be modified by forming their corresponding acid or base salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acids salts of basic residues (such as amines), or alkali or organic salts of acidic residues (such as carboxylic acids), and the like.
The salt forms differ from the compound described herein in certain physical properties such as solubility, but the salts are otherwise equivalent for purposes of this invention.
The term “pharmaceutically acceptable solvates” refers to solvates with water (i.e. hydrates, hemihydrate or sesquihydrate) or pharmaceutically acceptable solvents, for example solvates with common organic solvents as ethanol and the like. Such solvates are also encompassed within the scope of the disclosure.
The present invention also includes within its scope prodrugs of these compounds. In general, such prodrugs will be functional derivatives of these compounds, which are readily convertible in vivo into the required compound. Conventional procedures for the selection and preparation of prodrugs are known.
The disclosed compounds may get metabolized in vivo and these metabolites are also encompassed within the scope of this invention.
The term “polymorphs” includes all crystalline form as well as amorphous form for compounds described herein and as such are intended to be included in the present invention.
All isomers of the compounds of the invention are contemplated, either in admixture or in pure or substantially pure form.
The compounds of the present invention can have asymmetric centers at any of the carbon atoms including all the substituents. Consequently, compounds of present invention can exist in enantiomeric or diastereomeric forms or in mixture thereof. The processes for the preparation can utilize racemates, enantiomers, or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods, for example, chromatographic or fractional crystallization.
The term “tautomer” includes one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. Certain compounds of the general Formula (I) may furthermore be present in tautomeric forms.
The term “regioisomers” refers to compounds, which have the same molecular formula but differ in the connectivity of the atoms.
The term “compounds of the invention” and equivalent expressions, are meant to embrace compounds of Formula (I) as herein described, including pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, tautomers, racemates, regioisomers, prodrugs, metabolites, polymorphs or N-oxides, thereof, where the context so permits. In general and preferably, the compounds of the invention and the formulas designating the compounds of the invention are understood to only include the stable compounds thereof and exclude unstable compounds, even if an unstable compound might be considered to be literally embraced by the compound formula. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts and solvates, where the context so permits.
The term “stable compound” means a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic or diagnostic agent. For example, a compound, which would have a “dangling valency” or is a “carbanion” is not a compound contemplated by the invention.
The term “racemate” includes a mixture of equal amounts of left- and right-handed stereoisomers of chiral molecules.
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring.
The present disclosure includes all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.
The compounds of this invention are administered in conventional dosage forms prepared by combining active ingredient in an amount sufficient to produce 5-lipoxygenase pathway inhibiting activity with one or more non-toxic pharmaceutically acceptable carriers, adjuvants, diluents or vehicles, which are collectively referred to herein as carriers, according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carriers may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, and sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
The compositions can be administered orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously), intracisternally, intravaginally, intraperitoneally, topically or by inhalation.
Solid dosage forms for oral administration may be presented in discrete units, for example, capsules, cachets, lozenges, tablets, pills, powders, dragees or granules, each containing a predetermined amount of the active compound. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
Solid dosage forms can be prepared with coatings and shells, such as enteric coatings and others well known in this art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes.
The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters, of sorbitan or mixtures of these substances, and the like.
Besides such inert diluents, the composition can also include adjuvants, for example, wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents, colorants or dyes.
Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
Dosage forms for topical administration of a compound of this invention include powder, spray, inhalant, ointment, creams, salve, jelly, lotion, paste, gel, aerosol, or oil. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants as may be required. Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
Compositions suitable for parenteral injection may comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. These preparations may contain anti-oxidants, buffers, bacteriostats and solutes, which render the compositions isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried or lyophilized condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monosterate and gelatin.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients. The compositions can be administered by the nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered nasally from devices which deliver the formulation in an appropriate manner.
Suppositories for rectal administration of the compound of formula (I) can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and which therefore melt in the rectum or vaginal cavity and release the drug.
If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
Actual dosage levels of active ingredient in the compositions of the invention and spacing of individual dosages may be varied so as to obtain an amount of active ingredient that is effective to obtain a desired therapeutic response for a particular composition and method of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the compound chosen, the body weight, general health, sex, diet, route of administration, the desired duration of treatment, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated and is ultimately at the discretion of the physician.
Where desired, the compounds of Formula I and/or their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, tautomers, racemates, regioisomers, prodrugs, metabolites, polymorphs or N-oxides may be advantageously used in combination with one or more other therapeutic agents. Examples of other therapeutic agents, which may be used in combination with compounds of Formula I of this invention and/or their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, tautomers, racemates, regioisomers, prodrugs, metabolites, polymorphs or N-oxides include but are not limited to, muscarinic receptor antagonists, PDE4 inhibitors/PDE3/4 inhibitors/PDE4B inhibitors/PDE7 inhibitors, MMP9/12 inhibitors, caspase-1 inhibitors, beta 2 adrenoreceptor agonists, corticosteroids, p38 mitogen activated protein kinases, nuclear factor kappa B inhibitors, I kappa kinase inhibitors, VLA4 antagonists, thromboxane A2 antagonists, COX inhibitors, neutrophil elastase inhibitors, tachykinin receptor antagonists, secretory leukoprotease inhibitors, prostaglandin E analogues, adhesion molecule inhibitors, lipoxin agonists, tumour necrosis factor (TNF) inhibitors and other inflammatory cytokine inhibitors, chemokine inhibitors and chemokine receptor inhibitors, adenosine receptor antagonists, platelet activating factor antagonists, histamine release inhibitors, histamine receptor antagonists, nitric oxide synthase inhibitors, neurokinin antagonists or syk tyrosine kinase inhibitors.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention. The examples are provided to illustrate particular aspects of the disclosure and do not limit the scope of the invention.
1-Hydroxybenzotriazole (HOBT, 13.82 g, 102.3 mmol), N-ethyldiisopropyl amine (Hunig's base, 13.22 g, 102.3 mmol) and ammonium carbonate (27.0 g, 279.0 mmol) were added to a solution of (3-bromophenyl)acetic acid (20.0 g, 93.0 mmol) in freshly dried and distilled tetrahydrofuran (80 ml) under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for about 5 min and then cooled to 0° C. and stirred at the same temperature for about 1 hour. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI.HCl, 19.61 g, 102.3 mmol) was added to it at 0° C. under nitrogen atmosphere. The reaction mixture was stirred at room temperature for about 12 hours. The solvent was evaporated under vacuum and water was added to it. A white solid was obtained which was filtered, washed with water and dried. Yield: 12.69 g.
1H NMR (400 MHz, DMSO-d6): δ 7.52 (brs, 1H, —NH), 7.46 (s, 1H, Ar—H), 7.43-7.40 (m, 2H, Ar—H), 7.25-7.18 (m, 2H, Ar—H), 6.95 (brs, 1H, —NH) and 3.34 (s, 2H, —CH2).
Mass Spectrum (m/z, +ve ion mode): 214 [M++1]
2-(3-Bromophenyl)acetamide (10.0 g, 46.73 mmol) (example 1) in dry 1,4-dioxane (100 ml) was cooled to 0° C. Triethylamine (18.91 g, 187.92 mmol) was added to it and the reaction mixture was stirred for about 10 minutes. Trifluoroacetic anhydride (39.26 g, 186.92 mmol) was added dropwise to this solution at 0° C. and then the reaction mixture was stirred at room temperature for about 12 hours. It was poured into cold water, extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulphate, filtered and the solvent evaporated under vacuum. An oily residue was obtained which was purified by column chromatography over silica gel using ethyl acetate and hexane (1:49) to afford the title compound as light yellow colored oil. Yield: 8.4 g.
1H NMR (300 MHz, CDCl3): δ 7.49-7.46 (m, 2H, Ar—H), 7.27-7.23 (m, 2H, Ar—H) and 3.73 (s, 2H, —CH2CN).
Mass Spectrum (m/z, +ve ion mode): 197 [M++1]
(3-Bromophenyl)acetonitrile (10.0 g, 51.02 mmol) (example 2) was added dropwise to a cold solution (0° C.) of sodium hydride (60% dispersion is mineral oil) (4.49 g, 112.24 mmol) in dry distilled dimethylformamide (80 ml) under nitrogen atmosphere. The reaction mixture was stirred for about 30 minutes. 15-Crown-5 (1.01 g, 5.10 mmol) was added and the reaction mixture was stirred at 0° C. for about 30 minutes. Bis-(2-choroethyl)ether (7.17 ml, 61.22 mmol) and sodium iodide (7.65 g, 51.02 mmol) were added to it at 0° C. The reaction mixture was stirred overnight and quenched with water. It was extracted with ethyl acetate and the combined extracts were washed with water and brine. The organic layer was dried over anhydrous sodium sulphate, filtered and the solvent evaporated under reduced pressure to give an orange colored residue. The residue was purified by column chromatography over silica gel using ethyl acetate and hexane (1:4) to afford the title compound as light yellow crystalline solid. Yield: 11.20 g
1H NMR (300 MHz, CDCl3): δ 7.63 (s, 1H, Ar—H), 7.54-7.42 (m, 2H, Ar—H), 7.35-7.27 (m, 1H, Ar—H), 4.11 (m, 2H, —OCH2), 3.93-3.85 (m, 2H, —OCH2) and 2.16-2.02 (m, 4H) (2×—CH2).
A mixture of 4-(3-bromophenyl)tetrahydro-2H-pyran-4-carbonitrile (5.0 g, 18.79 mmol) (example 3), sodium carbonate (13.94 g, 131.58 mmol) and cesium carbonate (9.18 g, 28.19 mmol) was evacuated under vacuum for about 15 minutes. N-methyl pyrrolidinone (35 ml) and 4-aminothiophenol (2.8 g, 22.57 mmol) were added to this mixture under nitrogen atmosphere and heated at about 130° C. for about 15 hours. The mixture was cooled to room temperature, poured onto ice water and stirred. It was extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulphate, filtered and the solvent evaporated under vacuum to afford a brownish residue. Column chromatography over silica gel using ethyl acetate and hexane (3:2) gave the title compound as a light yellow solid. Yield: 6.2 g.
1H NMR (400 MHz, CDCl3): δ 7.34-7.20 (m, 5H, Ar—H), 7.03-7.00 (m, 1H, Ar—H), 6.72-6.70 (m, 2H, Ar—H), 4.07-3.90 (m, 2H, —OCH2), 3.90-3.84 (m, 4H, —OCH2 & 2×—NH) and 2.09-1.97 (m, 4H, 2×—CH2).
Mass Spectrum (m/z, +ve ion mode): 311 [M++1]
A mixture of 4-{3-[(4-aminophenyl)thio]phenyl}tetrahydro-2H-pyran-4-carbonitrile (2.50 g, 8.06 mmol) (example 4) in 1,2-dichloroethane (20 ml) and pyridine (0.95 g, 12.097 mmol) was cooled to 0° C. Phenyl chloroformate (1.89 g, 12.097 mmol) was added to the reaction mixture dropwise at 0° C. The reaction mixture was stirred at room temperature for about 1 hour. The solvent was evaporated under vacuum, toluene was added to remove traces of pyridine, then hexane was added and the solid so obtained was filtered and dried. Yield: 4.30 g.
1H NMR (400 MHz, CDCl3): δ 7.50-7.39 (m, 6H, Ar—H), 7.36-7.27 (m, 4H, Ar—H), 7.21-7.16 (m, 3H, Ar—H), 7.00 (brs, 1H, —NH), 4.09-4.06 (m, 2H, —OCH2), 3.92-3.85 (m, 2H, —OCH2) and 2.12-2.00 (m, 4H, 2×—CH2).
Mass Spectrum (m/z, +ve ion mode): 431 [M++1]
Hydrazine hydrate (99%, 0.44 g, 8.72 mmol) was added to a solution of phenyl(4-{[3-(4-cyanotetrahydro-2H-pyran-4-yl)phenyl]thio}phenyl)carbamate (1.50 g, 3.49 mmol) (example 5) in 1,4-dioxane (10 ml). The reaction mixture was refluxed at 110° C. for about 4 hours. The solvent was evaporated under vacuum and water was added to it. The white solid so obtained was filtered under vacuum and dried to obtain the title compound. Yield: 1.0 g
1H NMR (300 MHz, DMSO-d6): δ 8.86 (s, 1H, —NH), 7.66-7.63 (m, 2H, Ar—H), 7.53 (s, 1H, —NH), 7.39-7.35 (m, 2H, Ar—H), 7.04 (s, 1H, —NH), 4.39 (s, 1H, Ar—H), 4.00-3.96 (m, 2H, —OCH2), 3.65-3.57 (m, 2H, —OCH2) and 2.03-1.96 (m, 4H, 2×—CH2).
Mass Spectrum (m/z, +ve ion mode): 369 [M++1]
A mixture of N-(4-{[3-(4-cyanotetrahydro-2H-pyran-4-yl)phenyl]thio}phenyl)hydrazinecarboxamide (1.0 g, 2.72 mmol) (example 6) and acetamidine hydrochloride (1.16 g, 12.22 mmol) was evacuated for about 15 minutes. Dry dimethylformamide (10 ml) was added to it under nitrogen atmosphere and the mixture was heated at about 120° C. for about 7-8 hours. The solvent was evaporated under vacuum and a saturated solution of potassium carbonate was added till the mixture became basic. It was then extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulphate, filtered and the solvent evaporated under vacuum to afford a colorless oily residue. Column chromatography over silica gel using ethyl acetate and hexane (4:1) gave the title product as a white fluffy solid. Yield: 0.500 g.
1H NMR (300 MHz, CDCl3): δ 9.78 (brs, 1H, Ar—H), 7.57 (s, 1H, Ar—H), 7.44-7.39 (m, 4H, Ar—H), 7.32-7.24 (m, 3H, Ar—H), 4.10-4.07 (m, 2H, —OCH2), 3.93-3.86 (m, 2H, —OCH2), 2.16 (s, 3H, —CH3) and 2.13-1.97 (m, 4H, 2×—CH2)
Mass Spectrum (m/z, +ve ion mode): 393 [M++1]
A mixture of N-(4-{[3-(4-cyanotetrahydro-2H-pyran-4-yl)phenyl]thio}phenyl)hydrazinecarboxamide (2.0 g, 5.43 mmol) (example 6) and formamidine acetate (2.54 g, 24.45 mmol) was evacuated for about 15 minutes. Dry dimethylformamide (15 ml) was added under nitrogen atmosphere and the mixture was cooled to 0° C. Glacial acetic acid (5 ml) was added at 0° C. under nitrogen atmosphere and the mixture was stirred at room temperature for about 30 minutes. The contents of the reaction were then heated at about 120° C. for about 7-8 hours. The solvent was evaporated under vacuum and a saturated solution of sodium bicarbonate was added till the solution became basic. A white semisolid separated out. The reaction mixture was extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulphate, filtered and the solvent evaporated under vacuum to afford a light yellow solid, which upon crystallization in ethyl acetate and methanol gave the title compound as a light yellow solid. Yield: 1.60 g
1H NMR (400 MHz, DMSO-d6): δ 12.33 (brs, 1H, —NH), 9.87 (s, 1H, Ar—H), 7.77-7.75 (m, 2H, Ar—H), 7.56-7.35 (m, 5H, Ar—H), 7.27-7.25 (m, 1H, Ar—H), 4.02-3.98 (m, 2H, —OCH2), 3.67-3.60 (m, 2H, —OCH2) and 2.11-2.98 (m, 4H, 2×—CH2).
Mass Spectrum (m/z, +ve ion mode): 379 [M++1].
Solid potassium carbonate (0.158 g, 1.14 mmol) was added to a solution of 4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carbonitrile (0.100 g, 0.2544 mmol) (example 7) in dry dimethylformamide (2 ml). The reaction mixture was stirred at room temperature for about 5 minutes. Ethyl iodide (0.105 g, 0.763 mmol) was added to it and the mixture was heated at about 90-100° C. for about 12 hours. The solvent was evaporated under vacuum, water was added to it and the mixture extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate, filtered and the solvent evaporated under vacuum to afford a brown residue. The product was purified by preparative thin layer chromatography over silica gel, using ethyl acetate and hexane (3:2) as the eluant. Yield: 0.080 g.
1H NMR (300 MHz, CDCl3): δ 7.55 (s, 1H, Ar—H), 7.43-7.39 (m, 4H, Ar—H), 7.26-7.24 (m, 3H, Ar—H), 4.11-4.06 (m, 2H, —OCH2), 3.94-3.83 (m, 4H, —OCH2 & —NCH2), 2.17-2.02 (m, 7H, Ar—CH3 & 2×—CH2) and 1.37 (t, 3H, 6.0 Hz, —CH3).
Mass Spectrum (m/z, +ve ion mode): 421[M++1].
The following compounds were prepared similarly
Yield: 60 mg,
1HNMR (300 MHz, CDCl3): 7.56 (s, 1H, Ar—H), 7.41-7.06 (m, 7H, Ar—H), 4.11-4.07 (m, 2H, —OCH2), 3.93-3.86 (m, 2H, —OCH2), 3.49 (s, 3H, —NCH3), 2.16 (s, 3H, Ar—CH3) and 2.13-2.03 (m, 4H, 2×—CH2),
Yield: 100mg,
Mass Spectrum (m/z, +ve ion mode): 435 [M++1],
Yield: 100 mg,
Mass Spectrum (m/z, +ve ion mode): 435 [M++1],
Yield: 80 mg,
Mass Spectrum (m/z, +ve ion mode): 475 [M++1],
Yield: 90 mg,
Mass Spectrum (m/z, +ve ion mode): 449 [M++1],
Yield: 100 mg,
Mass Spectrum (m/z, +ve ion mode): 449 [M++1],
Yield: 95 mg,
Mass Spectrum (m/z, +ve ion mode): 447 [M++1],
Yield: 80 mg,
Mass Spectrum (m/z, +ve ion mode): 489 [M++1],
Yield: 100 mg,
Mass Spectrum (m/z, +ve ion mode): 461 [M++1],
Yield: 80 mg,
Mass Spectrum (m/z, +ve ion mode): 455 [M++1],
Yield: 80 mg,
Mass Spectrum (m/z, +ve ion mode): 437 [M++1],
Yield: 120 mg,
Mass Spectrum (m/z, +ve ion mode): 433 [M++1],
Yield: 100 mg,
Mass Spectrum (m/z, +ve ion mode): 506 [M++1],
Yield: 90 mg,
Mass Spectrum (m/z, +ve ion mode): 454 [M++23],
Yield: 50 mg,
1H NMR (300 MHz, CDCl3): δ 7.46-7.38 (m, 4H, Ar—H), 7.32-7.28 (m, 3H, Ar—H), 7.13-7.12 (m, 1H, Ar—H), 4.10-4.05 (m, 2H, —OCH2), 3.93-3.84 (m, 2H, —OCH2), 3.07 (s, 3H, Ar—CH3), 2.97-2.90 (m, 1H, —NCH) and 2.12-1.64 (brm, 16H, 8×—CH2),
The following compounds were prepared by following procedure of example 9 by using
Yield: 90 mg,
Mass Spectrum (m/z, +ve ion mode): 393 [M++1],
Yield: 85 mg,
Mass Spectrum (m/z, +ve ion mode): 407 [M++1],
Yield: 95 mg,
1H NMR (400 MHz, CDCl3): δ 7.96 (s, 1H, Ar—H), 7.70-7.55 (m, 2H, Ar—H), 7.49-7.37 (m, 5H, Ar—H), 7.29-7.26 (m, 1H, Ar—H), 4.10-4.07 (m, 2H, —OCH2), 3.92-3.81 (m, 4H, —OCH2 & —NCH2), 2.11-2.05 (m, 4H, 2×—CH2), 1.86-1.80 (m, 2H, —CH2) and 0.98 (t, 3H, J=8.00 Hz, —CH3),
Mass Spectrum (m/z, +ve ion mode): 421 [M++1],
Yield: 70 mg,
Mass Spectrum (m/z, +ve ion mode): 421[M++1],
Yield: 70 mg,
Mass Spectrum (m/z, +ve ion mode): 435 [M++1],
Yield: 87 mg,
Mass Spectrum (m/z, +ve ion mode): 435 [M++1],
Yield: 60 mg,
Mass Spectrum (m/z, +ve ion mode): 419 [M++1],
Yield: 60 mg,
Mass Spectrum (m/z, +ve ion mode): 433 [M++1],
Yield: 80 mg,
1HNMR (400 MHz, CDCl3): δ 7.68 (s, 1H, Ar—H), 7.56-7.54 (m, 2H, Ar—H), 7.49-7.46 (m, 6H, Ar—H), 4.70 (m, 1H, —NCH), 4.10-4.06 (m, 2H, —OCH2), 3.92-3.85 (m, 2H, —OCH2), 2.10-2.02 (m, 6H, 3×—CH2) and 1.93-1.88 (brm, 6H, 3×—CH2).
Yield: 95 mg,
Mass Spectrum (m/z, +ve ion mode): 461 [M++1],
Yield: 90 mg,
Mass Spectrum (m/z, +ve ion mode): 475 [M++1],
Yield: 85 mg,
Mass Spectrum (m/z, +ve ion mode): 475 [M++1],
Yield: 65 mg,
Mass Spectrum (m/z, +ve ion mode): 419 [M++1],
Yield: 78 mg,
Mass Spectrum (m/z, +ve ion mode): 417 [M++1],
Yield: 75 mg,
Mass Spectrum (m/z, +ve ion mode): 423 [M++1].
Solid potassium hydroxide (0.035 g, 0.6333 mmol) was added to a solution of 4-(3-{[4-(4-ethyl-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carbonitrile (0.070 g, 0.166 mmol) (example 9) in isopropyl alcohol and methanol mixture (3 ml). The reaction mixture was heated at about 90-100° C. for about 12-15 hours. The solvent was evaporated under vacuum and water was added. A white solid separated out, which was filtered and dried under vacuum to afford the title compound. Yield: 0.045 g.
1HNMR (300 MHz, CDCl3): δ 7.40-7.29 (m, 10H, Ar—H & 2×—NH), 3.88-3.75 (m, 6H, 2×—OCH2 & —NCH2), 2.36-2.32 (m, 2H, —CH2), 2.16 (s, 3H, Ar—CH3), 2.10-2.05 (m, 2H, —CH2) and 1.37 (t, 3H, J=6.0 Hz, —CH3).
Mass Spectrum (m/z, +ve ion mode): 439 [M++1]
The following compounds were prepared similarly:
Yield: 55 mg,
Mass Spectrum (m/z, +ve ion mode): 467 [M++1],
Yield: 40 mg,
Mass Spectrum (m/z, +ve ion mode): 479 [M++1],
Yield: 40 mg,
Mass Spectrum (m/z, +ve ion mode) :453 [M++1],
Yield: 40 mg,
Mass Spectrum (m/z, +ve ion mode): 453 [M++1],
Yield: 40 mg,
Mass Spectrum (m/z, +ve ion mode): 467 [M++1],
Yield: 30 mg,
Mass Spectrum (m/z, +ve ion mode): 451 [M++1],
Yield: 40 mg,
Mass Spectrum (m/z, +ve ion mode): 524 [M++1],
Yield: 12 mg,
Mass Spectrum (m/z, +ve ion mode): 473 [M++1],
Yield: 40 mg,
Mass Spectrum (m/z, +ve-ion mode): 507 [M++1],
Yield: 10 mg,
Mass Spectrum (m/z, +ve ion mode): 455 [M++1],
Yield: 10 mg,
Mass Spectrum (m/z, +ve ion mode): 493 [M++1],
Yield: 30 mg,
Mass Spectrum (m/z, +ve ion mode): 411 [M++1],
Yield: 32 mg,
Mass Spectrum (m/z, +ve ion mode): 425 [M++1],
Yield: 30 mg,
1H NMR (400 MHz, CDCl3+CD3OD): δ 8.12 (s, 1H, Ar—H), 7.5-7.14 (m, 8H, Ar—H), 7:14 (brs, 1H, —NH), 3.85-3.81 (m, 4H, 2×—OCH2), 3.75-3.70 (m, 2H, —NCH2), 2.42-2.39 (m, 2H, —CH2), 2.07-2.00 (m, 2H, —CH2), 1.88-1.79 (m, 2H, —CH2) and 0.99 (t, 3H, J=8.00 Hz, —CH3),
Mass Spectrum (m/z, +ve ion mode): 439 [M++1],
Yield: 30 mg,
Mass Spectrum(m/z, +ve ion mode): 451 [M++1],
Yield: 30 mg,
Mass Spectrum (m/z, +ve ion mode): 439 [M++1],
Yield: 33 mg,
Mass Spectrum (m/z, +ve ion mode): 453 [M++1],
Yield: 25 mg,
Mass Spectrum (m/z, +ve ion mode): 465 [M++1],
Yield: 35 mg,
Mass Spectrum (m/z, +ve ion mode): 453 [M++1],
Yield: 15 mg,
Mass Spectrum (m/z, +ve ion mode): 479 [M++1],
Yield: 27 mg,
Mass Spectrum (m/z, +ve ion mode): 493 [M++1],
Yield: 23 mg,
Mass Spectrum (m/z, +ve ion mode): 493 [M++1],
Yield: 32 mg,
Mass Spectrum (m/z, +ve ion mode): 437 [M++1],
Yield: 30 mg,
Mass Spectrum (m/z, +ve ion mode): 441 [M++1].
The following compound was prepared by following the procedure of example 10 by using 4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carbonitrile (example 7).
Yield: 30 mg,
Mass Spectrum (m/z, +ve ion mode): 411 [M+1].
N,N-Dimethylformamide dimethyl acetal (15 ml) was added to 4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxamide (2.0 g, 4.88 mmol) (example 10) and the reaction mixture was refluxed for about 2 hours. The solvent was evaporated under reduced pressure to obtain a light brown paste. Yield: 3.0 g. The following compound was prepared similarly by using N,N-dimethylacetamide dimethyl acetal.
Yield: 1.20 g.
Hydrazine dihydrochloride (1.13 g, 10.75 mmol) in sodium hydroxide solution (5N, 3 ml) was added to a solution of N-[(1E)-(dimethylamino)methylene]-4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxamide (3.0 g, 2.15 mmol) (example 11) in 1,4-dioxane. Glacial acetic acid (30 ml, 70%) was added to it and the reaction mixture was stirred at room temperature for about 30 minutes and then at 90° C. for about 5 hours. The solvent was evaporated under vacuum and a saturated solution of sodium bicarbonate was added till the solution became basic. The reaction mixture was extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulphate, filtered and the solvent evaporated under vacuum to afford a thick oily residue, which upon column chromatography over silica gel using methanol and ethyl acetate (1:19) afforded the title compound as white crystalline solid. Yield: 1.10 g
1H NMR (400 MHz, CDCl3): δ 10.55 (s, 1H, —NH), 8.23 (s, 1H, Ar—H), 7.40-7.34 (m, 4H, Ar—H), 7.29-7.18 (m, 4H, Ar—H), 6.58 (s, 1H, —NH), 3.91-3.89 (m, 2H, —OCH2), 3.51-3.46 (m, 2H, —OCH2), 2.60-2.57 (m, 2H, —CH2), 2.27-2.20 (m, 2H, —OCH2) and 2.06 (s, 3H, Ar—CH3).
Mass Spectrum (m/z, +ve ion mode): 435 [M++1]
A solution of hydroxylamine hydrochloride (0.522 g, 7.52 mmol) in sodium hydroxide (1M, 10 ml) was added to N-[(1E)-1-(dimethylamino)ethylidene]-4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxamide (1.20 g, 2.51 mmol) (example 11). It was then diluted with 1,4-dioxane (7.5 ml) followed by glacial acetic acid (10 ml) and the reaction mixture stirred for about 30 minutes at room temperature. The mixture was then heated at 90° C. for about 10 hours. The solvent was evaporated under vacuum and a saturated solution of potassium carbonate was added till the solution became basic. The reaction mixture was extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulphate, filtered and the solvent evaporated under vacuum to afford a thick oily residue which upon column chromatography over silica gel using ethyl acetate and hexane (4:1) gave the title compound as a thick oil. Yield: 0.60 g
1H NMR (300 MHz, CDCl3): δ 7.45 (s, 1H, Ar—H), 7.35-7.31 (m, 6H, Ar—H), 7.22-7.19 (m, 1H, Ar—H), 3.99-3.95 (m, 2H, —OCH2), 3.68-3.51 (m, 2H, —OCH2), 3.48 (s, 3H, Ar—CH3), 2.73-2.68 (m, 2H, —CH2), 2.31 (s, 3H, Ar—CH3), 2.30-2.21 (m, 2H, —CH2) and 2.15 (s, 3H, Ar—CH3).
Mass Spectrum (m/z, +ve ion mode): 464 [M++1]
Solid potassium carbonate (0.127 g, 0.9216 mmol) was added to a solution of 5-methyl-2-[4-({3-[4-(4H-1,2,4-triazol-3-yl)tetrahydro-2H-pyran-4-yl]phenyl}thio)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (0.100 g, 0.2304 mmol) (example 12) in dry dimethylformamide (3 ml). The reaction mixture was stirred at room temperature for about 5 minutes. N-Propyl bromide (0.113 g, 0.9216 mmol) was added to it and the mixture was heated at 90°-100° C. for about 12 hours. The solvent was evaporated under vacuum, water was added to it and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate, filtered and the solvent evaporated under vacuum to afford an oily residue. The product was purified by preparative thin layer chromatography using ethyl acetate and hexane (1:1) as the eluant to get the title compound as white solid. Yield: 70 mg.
1H NMR (CDCl3, 400 MHz): δ 8.08 (s, 1H, Ar—H), 7.42-7.16 (m, 8H, Ar—H), 4.10-4.07 (t, 2H, J=7.00Hz, —NCH2), 3.90-3.78 (m, 2H, —OCH2), 3.76-3.74 (m, 4H, —OCH2 & —NCH2), 2.68 (m, 2 H, —CH2), 2.16-2.14 (m, 5H, —CH2 & Ar—CH3), 1.89-1.78 (m, 4H, 2×—CH2), 0.97 (t, 3H, J=8.00 Hz, —CH3) and 0.89 (t, 3H, J=8.00 Hz, —CH3).
Mass Spectrum (m/z, +ve ion mode): 519 [M++1].
The following compounds were prepared similarly
Mass Spectrum (m/z, +ve ion mode): 463 [M++1],
Mass Spectrum (m/z, +ve ion mode): 491 [M++1],
Mass Spectrum (m/z, +ve ion mode): 519 [M++1],
Mass Spectrum (m/z, +ve ion mode): 547 [M++1],
Mass Spectrum (m/z, +ve ion mode): 547 [M++1],
Mass Spectrum (m/z, +ve ion mode): 571 [M++1],
Mass Spectrum (m/z, +ve ion mode): 599 [M++1],
Mass Spectrum (m/z, +ve ion mode): 627 [M++1],
Mass Spectrum (m/z, +ve ion mode): 515 [M++1].
Potassium hydroxide (3.0 mmol) is added to a solution of 4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxamide (1.0 mmol) (example 10) in methanol and tetrahydrofuran (1:2) and the reaction mixture is refluxed for about 18 hours. The solvent is evaporated under vacuum. A small amount of water and concentrated hydrochloric acid are added to the residue to separate out the title compound.
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI. HCl) (1.0 mmol) is added to a mixture of 4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxylic acid (1.0 mmol) (example 15), 1-hydroxybenzotriazole (1.0 mmol), N-methylmorpholine (1.65 mmol) and propargylamine (1.0 mmol) in dichloromethane-dimethylformamide (1:1) at 0° C. The solution is stirred overnight at room temperature, washed with water and the aqueous layer is extracted with dichloromethane. The combined organic extracts are dried with sodium sulphate, filtered and the solvent is evaporated under reduced pressure. The residue is purified by column chromatography over silica gel to yield the title product.
A solution of 4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)-N-prop-2-yn-1-yltetrahydro-2H-pyran-4-carboxamide (1.0 mmol) (example 16) and mercuric acetate (0.11 mmol) in acetic acid is heated at reflux for about 3 hours. All the volatiles are removed under reduced pressure and an aqueous solution of saturated potassium carbonate is added to the residue. The mixture is then extracted with dichloromethane, and the organic layer is dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The residue is then purified by column chromatography over silica gel to yield the title compound.
Solid potassium carbonate (4.5.mmol) is added to a solution of 5-methyl-2-[4-({3-[4-(5-methyl-1,3-oxazol-2-yl)tetrahydro-2H-pyran-4-yl]phenyl}thio)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (1.0 mmol) (example 17) in dry dimethylformamide. The reaction mixture is stirred a room temperature for about 15 minutes. Methyl iodide (3.0 mmol) is added to it and the reaction mixture is heated at about 100° C. for about 12 hours. The solvent is evaporated under vacuum, water is added and the reaction mixture is extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulphate, filtered and the solvent is evaporated to afford the residue. Column chromatography of the residue over silica gel affords the title compound.
Ethanol is added to a solution of 4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxylic acid (1.0 mmol) (example 15) and the reaction mixture is cooled to 0° C. The contents are stirred for about 15 minutes. Thionyl chloride (1.2 mmol) is added dropwise at 0° C. and the reaction mixture is stirred at room temperature for about 2 hours. The solvent is evaporated under vacuum, dichloromethane is added and the contents are washed with a cold solution of sodium bicarbonate. The organic layer is dried over sodium sulphate, filtered and the solvent is evaporated to afford the title compound.
2-Ethanolamine (6.0 mmol) is added to a solution of ethyl 4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxylate (1.0 mmol) (example 19) in ethanol and the contents are refluxed. All the volatiles are removed under reduced pressure and the residue is, purified by column chromatography over silica gel to afford the title compound.
Triethylamine (5.0 mmol) and carbon tetrachloride (5.0 mmol) are added dropwise to a solution of N-(2-hydroxyethyl)-4-(3-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxamide (1.0 mmol) (example 20) in acetonitrile. The reaction mixture is stirred at room temperature for about 3 hours. The solution is filtered and the filtrate is concentrated under reduced pressure to afford the residue. Column chromatography of the residue over silica gel affords the title compound.
Solid potassium carbonate (4.5 mmol) is added to a solution of 2-[4-({3-[4-(4,5-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)tetrahydro-2H-pyran-4-yl]phenyl}thio)phenyl]-5-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one (1.0 mmol) (example 21) in dry dimethylformamide. The reaction mixture is stirred a room temperature for about 15 minutes. Methyl iodide (3.0 mmol) is added to it and the reaction mixture is heated at about 100° C. for about 12 hours. The solvent is evaporated under vacuum, water is added and the reaction mixture is extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulphate, filtered and the solvent is evaporated to afford the residue. Column chromatography of the residue over silica gel affords the title compound.
Assay was carried out in 96 well UV plate containing 100 μL reaction mixture 1,4-dithiothreitol (DTT) 200 μM; adenosine triphosphate (ATP), 100 μM; and calcium chloride, 100 μM; in phosphate buffered saline in the absence and presence of different concentrations of test compound (10 nM-10 μM) and 12 U (3 U μl−1) of human recombinant 5-lipoxygenase (Cayman Chemicals Co., USA). The reaction mixture was incubated at 37° C. for 5 min, and reaction initiated by adding 1 μl of 1 mM freshly prepared arachidonic acid. Increase in absorbance was monitored at 234 nm for 10 minutes. (J. Biol. Chem., 261, 11512-11519, 1986). A plot of absorbance vs. time curve was prepared and area under curve (AUC) was computed for each well. Percent inhibition of AUC for different treatments was calculated with respect to the difference between the arachidonic acid stimulated and negative control values, to compute IC50 values. The assay was repeated with the same protocol in the absence of DTT to mimic non-reducing condition and IC50 values were computed. IC50 values for some of the compounds was found to be in the range of low nM to >10 μM.
Cell Based Assay: A23187 Induced LTB4 Release
Neutrophils were isolated from freshly drawn human blood after dextran sedimentation and ficoll separation (Eur. J. Biochem., 169, 175, 1987). Neutrophil suspension (0.2×106 cells/ml) was incubated in polystyrene microtitre plates with test compound in a 24 well plate and incubated at 37° C. for 1 hr. and 0.25 mM Ca++/Mg++ was added in the final 3 min of incubation period. The reaction was initiated by adding 0.3 μg ml−1 A23187 (Sigma-Aldrich Co, USA) and continued for 10 min at 37° C. The reaction was stopped by adding 80 μL of cold methanol (J. Pharmacol. Exp. Ther. 297, 267, 2001). The samples were analysed for LTB4 assay using LTB4 ELISA kits. The amount of LTB4 released was quantified and percent inhibition of LTB4 release was calculated with respect to the difference between the A23187 stimulated and negative control cells, to compute IC50 values. IC50 values for some of the compounds was found to be in the range of low nM to >10 μM.
| Number | Date | Country | Kind |
|---|---|---|---|
| 699/DEL/2005 | Mar 2006 | IN | national |
